Valuation dashboard for KalVista Pharmaceuticals, Inc. (KALV) with P/E N/A, P/B -503.31, EV/EBITDA -12.74 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P.
Analysis Summary
Trailing-twelve-month margins: gross margin 92.0%, operating margin -120.8%, net margin -119.4%.
At the current price of $27.00, KALV has negative trailing earnings (P/E not meaningful) and an ROE of -10.57%. Market capitalisation stands at $1.4B.
Balance sheet quality for KALV: current ratio of 5.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -503.31 |
| EV / EBITDA | -12.74 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $47.94 |
| vs Current Price | +77.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KALV | KalVista Pharmaceuticals, Inc. | $1.4B | -10.6% | ||
| KRYS | Krystal Biotech, Inc. | $9.9B | 39.88 | 7.17 | |
| PTGX | Protagonist Therapeutics, Inc. | $9.2B | 8.71 | -21.2% | |
| COGT | Cogent Biosciences, Inc. | $5.7B | 10.45 | -72.6% | |
| SRRK | Scholar Rock Holding Corporation | $5.9B | 22.93 | -160.2% | |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.8B | 70.23 | 8.91 | 13.7% |
Price
| Price | $27.00 |
| Market Cap | $1.4B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -1057.44% |
| Return on Invested Capital | -46.81% |
| Return on Assets | -41.28% |
| Gross Margin | 92.03% |
| Operating Margin | -120.80% |
| Net Margin | -119.44% |
Related companies: COGT · KNSA · KRYS · KURA · LRMR · PTGX · SRRK
Explore sector: Healthcare · Biotechnology
More sections of KALV: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks